The South Carolina Clinical and Translational Institute
Dr. Kathleen T. Brady, Associate Provost for Clinical and Translational Science at MUSC and Director of the South Carolina Clinical and Translational Institute
The Medical University of South Carolina is fortunate to be one of only about 60 institutions in the nation chosen by the National Institutes of Health to receive a Clinical and Translational Science Award (CTSA). In the words of its director Kathleen T. Brady, M.D., PhD, The South Carolina Clinical and Translational Institute (SCTR), founded in 2009 using CTSA funds, is intended, “to act as a catalyst to ensure that discoveries that originate in laboratories at academic medical centers are translated in a way that leads to practical applications that can really have an impact on health.”
In the five years since its founding, SCTR has sped the translation of discovery into care by assisting with every stage of the research process, including grant submissions, institutional review board applications, clinical trial conduct, and product commercialization. Successful examples of translation are the first new lupus drug in 52 years (Principal Investigator: Gary S. Gilkeson, M.D.) and the first U.S. study of bronchial coils for emphysema (Principal Investigator: Charlie B. Strange III, M.D.).
In terms of entrepreneurial activities, SCTR’s Center for Innovation and Entrepreneurship has assisted with 314 intellectual property disclosures, 67 new patent applications, and 15 start-up companies.